Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review

Bulletin du cancer
Océane ClergueMarc Debled

Abstract

BRCA1 and BRCA2 mutations account for 40% of cancer predisposition gene mutations identified in the current French diagnostic setting. The proteins encoded by these genes are implicated in DNA repair pathways. As a result, loss of BRCA1 or BRCA2 function may modify chemo-sensitivity. This literature review aims to determine whether BRCA1 mutation status should influence the choice of systemic treatment in breast cancer. Fourteen articles and four abstracts from 12 retrospective analyses and 6 prospective studies were identified in the literature review. CMF-type and taxane-based protocols appear to be insufficiently effective, while anthracycline activity does not seem to be affected by BRCA1 status. BRCA1-mutated tumours appear to be highly sensitive to platinum, in both the neoadjuvant and metastatic setting. Olaparib, a PARP inhibitor, has only been evaluated in one study in metastatic patients, with promising results. The presence of a BRCA1 mutation can lead to an adaptation of therapies in the metastatic stages in breast cancer. The rapid identification of BRCA1 mutations and the adaptation of treatment according to this status in the (neo)adjuvant setting is likely to become a reality in the coming years.

References

Aug 6, 2002·Journal of Medical Genetics·P O ChappuisW D Foulkes
Nov 18, 2004·Journal of the National Cancer Institute·Richard D KennedyD Paul Harkin
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roman RouzierLajos Pusztai
Jun 1, 2006·Familial Cancer·William D Foulkes
May 12, 2007·Breast Cancer Research and Treatment·T ByrskiUNKNOWN Polish Hereditary Breast Cancer Consortium
Jul 24, 2008·Breast Cancer Research and Treatment·T ByrskiS A Narod
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Jul 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mieke KriegeJan G M Klijn
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tomasz ByrskiSteven Narod
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Banu ArunConstance Albarracin
Nov 14, 2012·Breast Cancer Research : BCR·Nicholas C Turner, Andrew N J Tutt
Jan 10, 2014·Journal of the National Cancer Institute·Jude M MulliganRichard D Kennedy
Apr 3, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DelalogeJ Lubinski
Aug 19, 2014·Breast Cancer Research and Treatment·T ByrskiS A Narod

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Risk Factors

Breast cancer is a multifactorial disease that is influenced by both environmental and genetic factors. Discover the latest research on the environmental and genetic risk factors for breast cancer here.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.